{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T07:49:20Z","timestamp":1791186560258,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1007\/s11523-015-0359-8","type":"journal-article","created":{"date-parts":[[2015,1,31]],"date-time":"2015-01-31T02:28:37Z","timestamp":1422671317000},"page":"141-151","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Idelalisib: a review of its use in chronic lymphocytic leukaemia and indolent non-Hodgkin\u2019s lymphoma"],"prefix":"10.1007","volume":"10","author":[{"given":"Gillian M.","family":"Keating","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,2,1]]},"reference":[{"key":"359_CR1","unstructured":"National Comprehensive Cancer Network (2014) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): non-Hodgkin\u2019s lymphoma (version 5.2014). https:\/\/www.nccn.org . Accessed 17 Dec 2014"},{"issue":"15","key":"359_CR2","doi-asserted-by":"crossref","first-page":"4013","DOI":"10.1158\/1078-0432.CCR-11-1402","volume":"18","author":"SEM Herman","year":"2012","unstructured":"Herman SEM, Johnson AJ (2012) Molecular pathways: targeting phosphoinositide 3-kinase p110-delta in chronic lymphocytic leukemia. Clin Cancer Res 18(15):4013\u20138","journal-title":"Clin Cancer Res"},{"key":"359_CR3","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3389\/fimmu.2012.00224","volume":"3","author":"SD Pauls","year":"2012","unstructured":"Pauls SD, Lafarge ST, Landego I et al (2012) The phosphoinositide 3-kinase signaling pathway in normal and malignant B cells: activation mechanisms, regulation and impact on cellular functions. Front Immunol 3:224","journal-title":"Front Immunol"},{"issue":"1","key":"359_CR4","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11899-013-0189-7","volume":"9","author":"JE Chang","year":"2014","unstructured":"Chang JE, Kahl BS (2014) PI3-kinase inhibitors in chronic lymphocytic leukemia. Curr Hematol Malig Rep 9(1):33\u201343","journal-title":"Curr Hematol Malig Rep"},{"key":"359_CR5","unstructured":"Gilead Sciences Inc. (2014) Zydelig\u00ae (idelalisib) tablets, for oral use: US prescribing information. http:\/\/www.zydelig.com . Accessed 17 Dec 2014"},{"key":"359_CR6","unstructured":"European Medicines Agency (2014) Zydelig (idelalisib) film-coated tablets: EU summary of product characteristics. http:\/\/www.ema.europa.eu\/ . Accessed 17 Dec 2014"},{"issue":"2","key":"359_CR7","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood-2010-03-275305","volume":"117","author":"BJ Lannutti","year":"2011","unstructured":"Lannutti BJ, Meadows SA, Herman SE et al (2011) CAL-101, a p110\u03b4 selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 117(2):591\u20134","journal-title":"Blood"},{"issue":"13","key":"359_CR8","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1182\/blood-2011-05-352492","volume":"118","author":"J Hoellenriegel","year":"2011","unstructured":"Hoellenriegel J, Meadows SA, Sivina M et al (2011) The phosphoinositide 3\u02b9-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 118(13):3603\u201312","journal-title":"Blood"},{"issue":"9","key":"359_CR9","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1182\/blood-2009-06-222943","volume":"116","author":"H Ikeda","year":"2010","unstructured":"Ikeda H, Hideshima T, Fulciniti M et al (2010) PI3K\/p110\u03b4 is a novel therapeutic target in multiple myeloma. Blood 116(9):1460\u20138","journal-title":"Blood"},{"issue":"17","key":"359_CR10","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1182\/blood-2012-02-414060","volume":"120","author":"MS Davids","year":"2012","unstructured":"Davids MS, Deng J, Wiestner A et al (2012) Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia. Blood 120(17):3501\u20139","journal-title":"Blood"},{"issue":"12","key":"359_CR11","doi-asserted-by":"crossref","first-page":"e83830","DOI":"10.1371\/journal.pone.0083830","volume":"8","author":"S Fiorcari","year":"2013","unstructured":"Fiorcari S, Brown WS, McIntyre BW et al (2013) The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells. PLoS ONE 8(12):e83830","journal-title":"PLoS ONE"},{"issue":"12","key":"359_CR12","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1182\/blood-2010-02-271171","volume":"116","author":"SEM Herman","year":"2010","unstructured":"Herman SEM, Gordon AL, Wagner AJ et al (2010) Phosphatidylinositol 3-kinase-\u03b4 inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 116(12):2078\u201388","journal-title":"Blood"},{"issue":"8","key":"359_CR13","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1182\/blood-2011-10-386763","volume":"119","author":"SA Meadows","year":"2012","unstructured":"Meadows SA, Vega F, Kashishian A et al (2012) PI3K\u03b4 inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma. Blood 119(8):1897\u2013900","journal-title":"Blood"},{"key":"359_CR14","doi-asserted-by":"crossref","unstructured":"Herter S, Palazzo A, Bacac M, et al. (2014) The PI3K delta selective inhibitor idelalisib does not interfere with immune effector function and B cell depletion mediated by obinutuzumab (GA101) and rituximab [abstract no. 3342]. In: 56th American Society of Hematology Annual Meeting and Exposition","DOI":"10.1182\/blood.V124.21.3342.3342"},{"key":"359_CR15","doi-asserted-by":"crossref","unstructured":"Jin F, Robeson M, Zhou H, et al. (2013) Evaluation of the effect of idelalisib on the QT\/QTC interval in healthy subjects [abstract no. 5573]. Blood 122(21)","DOI":"10.1182\/blood.V122.21.5573.5573"},{"key":"359_CR16","doi-asserted-by":"crossref","unstructured":"Webb HK, Chen H, Yu AS, et al. (2010) Clinical pharmacokinetics of CAL-101, a p110 isoform-selective P13K\u03b4 inhibitor, following single- and multiple-dose administration in healthy volunteers and patients with hematological malignancies [abstract no. 1774 plus poster]. Blood 116(21)","DOI":"10.1182\/blood.V116.21.1774.1774"},{"key":"359_CR17","doi-asserted-by":"crossref","unstructured":"Jin F, Robeson M, Zhou H, et al. (2013) Evaluation of drug interaction profile of idelalisib and its major circulating metabolite, GS-563117, in healthy subjects [abstract no. 5574]. Blood 122(21)","DOI":"10.1200\/jco.2014.32.15_suppl.2593"},{"key":"359_CR18","doi-asserted-by":"crossref","unstructured":"Jin F, Robeson M, Zhou H, et al. (2013) Pharmacokinetics, metabolism and excretion of idelalisib [abstract no. 5570]. Blood 122(21)","DOI":"10.1158\/1538-7445.AM2014-4633"},{"key":"359_CR19","doi-asserted-by":"crossref","unstructured":"Jin F, Robeson M, Zhou H, et al. (2013) The pharmacokinetics and safety of idelalisib in subjects with moderate or severe hepatic impairment [abstract no. 5571]. Blood 122(21)","DOI":"10.1158\/1538-7445.AM2014-CT204"},{"key":"359_CR20","doi-asserted-by":"crossref","unstructured":"Jin F, Robeson M, Zhou H, et al. (2013) The pharmacokinetics and safety of idelalisib in subjects with severe renal impairment [abstract no. 5572]. Blood 122(21)","DOI":"10.1158\/1538-7445.AM2014-CT204"},{"key":"359_CR21","doi-asserted-by":"crossref","unstructured":"Jin F, Robeson M, Zhou H, et al. (2013) Pharmacokinetics and safety of idelalisib, a novel PI3K\u03b4 inhibitor, in Japanese and Caucasian subjects [abstract no. 5575]. Blood 122(21)","DOI":"10.1158\/1538-7445.AM2014-CT217"},{"issue":"22","key":"359_CR22","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood-2013-11-535047","volume":"123","author":"JR Brown","year":"2014","unstructured":"Brown JR, Byrd JC, Coutre SE et al (2014) Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110\u03b4, for relapsed\/refractory chronic lymphocytic leukemia. Blood 123(22):3390\u20137","journal-title":"Blood"},{"key":"359_CR23","doi-asserted-by":"crossref","unstructured":"Barrientos JC, Furman RR, Leonard J, et al. (2013) Update on a phase I study of the selective PPI3K\u03b4 inhibitor idelalisib (GS-101) in combination with rituximab and\/or bendamustine in patients with relapsed or refractory CLL [abstract no. 7017 plus slide presentation]. J Clin Oncol 31(15 Suppl 1)","DOI":"10.1200\/jco.2013.31.15_suppl.7017"},{"key":"359_CR24","doi-asserted-by":"crossref","unstructured":"Furman RR, De Vos S, Leonard JP, et al. (2013) A phase 1 study of the selective PI3K\u03b4 inhibitor idelalisib (GS-1101) in combination with therapeutic anti-CD20 antibodies (rituximab or ofatumumab) in patients with relapsed or refractory chronic lymphocytic leukemia [abstract no. 4180]. Blood 122(21)","DOI":"10.1182\/blood.V122.21.4180.4180"},{"key":"359_CR25","unstructured":"Coutre S, Leonard J, Furman R, et al. (2013) Update on a phase I study of the selective PI3K-delta inhibitor, idelalisib (GS-1101) in combination with ofatumumab in patients with relapsed or refractory chronic lymphocytic leukaemia [abstract no. S1150]. In: 18th Congress of the European Hematology Association"},{"key":"359_CR26","doi-asserted-by":"crossref","unstructured":"Barrientos JC, Coutre SE, De Vos S, et al. (2014) Long-term follow-up of a phase I study evaluating the selective PI3K\u03b4 inhibitor idelalisib in combination with bendamustine (B), bendamustine\/rituximab (BR), fludarabine (F), chlorambucil (Chl), or chlorambucil\/rituximab (ChlR) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) [abstract no. 3343]. In: 56th American Society of Hematology Annual Meeting and Exposition","DOI":"10.1182\/blood.V124.21.3343.3343"},{"issue":"11","key":"359_CR27","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","volume":"370","author":"RR Furman","year":"2014","unstructured":"Furman RR, Sharman JP, Coutre SE et al (2014) Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 370(11):997\u20131007","journal-title":"N Engl J Med"},{"issue":"11","key":"359_CR28","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","volume":"370","author":"AK Gopal","year":"2014","unstructured":"Gopal AK, Kahl BS, de Vos S et al (2014) PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 370(11):1008\u201318","journal-title":"N Engl J Med"},{"key":"359_CR29","unstructured":"Pagel JM, Coutre SE, Furman RR, et al. (2014) Second interim analysis of a phase 3 study evaluating idelalisib plus rituximab for relapsed chronic lymphocytic leukemia (CLL) [poster]. In: Second Annual Meeting of the Society of Hematologic Oncology"},{"key":"359_CR30","doi-asserted-by":"crossref","unstructured":"Coutre SE, Furman RR, Sharman JP, et al. (2014) Second interim analysis of a phase 3 study evaluating idelalisib and rituximab for relapsed CLL [abstract no. 7012 plus poster]. J Clin Oncol 32(5 Suppl).","DOI":"10.1200\/jco.2014.32.15_suppl.7012"},{"key":"359_CR31","doi-asserted-by":"crossref","unstructured":"Sharman JP, Coutre SE, Furman RR, et al. (2014) 2nd interim analysis of a phase 3 study of idelalisib (Zydelig\u00ae) plus rituximab (R) for relapsed chronic lymphocytic leukemia (CLL): efficacy analysis in patient subpopulations with del(17p) and other adverse prognostic factors [abstract no. 330]. In: 56th American Society of Hematology Annual Meeting and Exposition","DOI":"10.1182\/blood.V124.21.330.330"},{"key":"359_CR32","doi-asserted-by":"crossref","unstructured":"Sharman JP, Coutre SE, Furman RR, et al. (2014) Efficacy of idelalisib in CLL subpopulations harboring del(17p) and other adverse prognostic factors: results from a phase 3, randomized, double-blind, placebo-controlled trial [abstract no. 7011 plus poster]. J Clin Oncol 32(15 Suppl 1)","DOI":"10.1016\/S0145-2126(14)70108-0"},{"key":"359_CR33","doi-asserted-by":"crossref","unstructured":"Ghia P, O\u2019Brien SM, Hillmen P, et al. (2014) Health-related quality of life (HRQL) impact of idelalisib (IDELA) in patients (pts) with relapsed chronic lymphocytic leukemia (CLL): phase 3 results [abstract no. 7099 plus poster]. J Clin Oncol 32(5 Suppl)","DOI":"10.1200\/jco.2014.32.15_suppl.7099"},{"key":"359_CR34","doi-asserted-by":"crossref","unstructured":"Xenakis A, Smith N, Beckerman R, et al. (2014) A decision-analytic model of idelalisib and rituximab combination therapy versus rituximab monotherapy in relapsed, unfit chronic lymphocytic leukemia [abstract no. 7101]. J Clin Oncol 32(15 Suppl 1)","DOI":"10.1200\/jco.2014.32.15_suppl.7101"},{"key":"359_CR35","doi-asserted-by":"crossref","unstructured":"Gopal AK, Kahl BS, de Vos S, et al. (2014) Mature follow up from a phase 2 study of PI3K-delta inhibitor idelalisib in patients with double (rituximab and alkylating agent)-refractory indolent B-cell non-Hodgkin lymphoma (iNHL) [abstract no. 1708]. In: 56th American Society of Hematology Annual Meeting and Exposition","DOI":"10.1182\/blood.V124.21.1708.1708"},{"issue":"22","key":"359_CR36","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1182\/blood-2013-11-538546","volume":"123","author":"IW Flinn","year":"2014","unstructured":"Flinn IW, Kahl BS, Leonard JP et al (2014) Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-\u03b4, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood 123(22):3406\u201313","journal-title":"Blood"},{"key":"359_CR37","doi-asserted-by":"crossref","unstructured":"Wagner-Johnston ND, Gopal AK, Kahl BS, et al. (2014) Patient-reported outcomes data from a phase 2 study of idelalisib in patients with refractory indolent B-cell non-Hodgkin lymphoma (iNHL) [abstract no. e19554]. J Clin Oncol 32(15 Suppl 1)","DOI":"10.1200\/jco.2014.32.15_suppl.e19554"},{"key":"359_CR38","doi-asserted-by":"crossref","unstructured":"Smith N, Xenakis A, Beckerman R, et al. (2014) A decision-analytic model of idelalisib in relapsed or refractory patients with indolent non-Hodgkin lymphoma [abstract no. e17655]. J Clin Oncol 32(15 Suppl 1)","DOI":"10.1200\/jco.2014.32.15_suppl.e17655"},{"key":"359_CR39","doi-asserted-by":"crossref","unstructured":"O\u2019Brien S, Lamanna N, Kipps TJ, et al. (2014) Update on a phase 2 study of idelalisib in combination with rituximab in treatment-naive patients \u226565\u00a0years with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) [abstract no. 1994]. In: 56th American Society of Hematology Annual Meeting and Exposition","DOI":"10.1182\/blood.V124.21.1994.1994"},{"key":"359_CR40","doi-asserted-by":"crossref","unstructured":"Zelenetz A, Lamanna N, Kipps T, et al. (2014) A phase 2 study of idelalisib monotherapy in previously untreated patients \u226565\u00a0years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) [abstract no. 1986 plus poster]. In: 56th American Society of Hematology Annual Meeting and Exposition","DOI":"10.1182\/blood.V124.21.1986.1986"},{"key":"359_CR41","doi-asserted-by":"crossref","unstructured":"de Vos S, Wagner-Johnston ND, Coutre SE, et al. (2014) Durable responses following treatment with the PI3K-delta inhibitor idelalisib in combination with rituximab, bendamustine, or both, in recurrent indolent non-Hodgkin lymphoma: phase I\/II results [abstract no. 3063]. In: 56th American Society of Hematology Annual Meeting and Exposition","DOI":"10.1182\/blood.V124.21.3063.3063"},{"issue":"23","key":"359_CR42","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1200\/JCO.2012.43.3748","volume":"30","author":"BD Cheson","year":"2012","unstructured":"Cheson BD, Byrd JC, Rai KR et al (2012) Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol 30(23):2820\u20132","journal-title":"J Clin Oncol"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-015-0359-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11523-015-0359-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-015-0359-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T02:16:12Z","timestamp":1651112172000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11523-015-0359-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,1]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["359"],"URL":"https:\/\/doi.org\/10.1007\/s11523-015-0359-8","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,1]]}}}